Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Novartis AG (NVS) Price & Performance

iShares iBoxx $ Inv Grade Corporate Bond ETFTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ Inv Grade Corporate Bond ETF vs Novartis AG — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.78, while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

	LQD	NVS
52-Week High	$112.91	$168.62
52-Week Low	$106.96	$113.50
Market Cap	—	$290.25B
Sector	—	Health
Enterprise Value	—	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LQD

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About iShares iBoxx $ Inv Grade Corporate Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.